Oncotarget

Clinical Research Papers:

Prognostic significance of the pretreatment serum gamma-glutamyltransferase levels in Chinese patients with non-metastatic cervical cancer

Yi Zhu, Ai-Jun Zhang, Da-Bao Wu, Zhen Shen, Gang Chen, Yang-Yang Shi, Hao Wu and Jing Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:115701-115708. https://doi.org/10.18632/oncotarget.22273

Metrics: PDF 436 views  |   HTML 1179 views  |   ?  


Abstract

Yi Zhu1, Ai-Jun Zhang1, Da-Bao Wu1, Zhen Shen1, Gang Chen1, Yang-Yang Shi1, Hao Wu1 and Jing Wang1

1Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated Anhui Medical University, Hefei, Anhui, 230001, People’s Republic of China

Correspondence to:

Jing Wang, email: wang19620909@126.com

Keywords: cervical cancer, serum gamma-glutamyltransferase, GGT, survival

Received: January 09, 2017     Accepted: September 18, 2017     Published: November 01, 2017

ABSTRACT

This study was performed to evaluate the prognostic significance of the pretreatment serum gamma-glutamyltransferase (GGT) levels in a Chinese cohort of patients with early-stage or locally advanced cervical cancer. The pretreatment serum GGT levels were examined in 290 cervical cancer patients with stage I-III disease and 230 healthy controls selected from a cancer-free population in the same region. Patients were assigned to normal or high-risk GGT groups, as previously described, and the GGT levels were correlated to clinicopathologic parameters and survival data. The GGT levels in cervical cancer patients were significantly higher than those in healthy controls (35.6 ± 29.1 vs. 24.1 ± 14.7 U/L, P < 0.001). In addition, the pretreatment serum GGT levels were associated with the histology type (P = 0.023), lymph node involvement (P = 0.040), stage (P = 0.029), recurrence (P = 0.015) and death (P = 0.005), but not with age (P = 0.432), tumor size (P = 0.067) or degree of differentiation (P = 0.901). Moreover, univariate survival analysis revealed that patients with high GGT levels tended to have poorer disease-free survival (DFS) [hazard ratio (HR), 1.721; 95% confidence interval (CI), 1.189–2.491; P = 0.004] and overall survival (OS) (HR, 1.929; 95% CI, 1.294–2.876; P = 0.001) compared to those with normal GGT levels. However, a multivariate Cox-regression model did not support these data (HR, 1.373; 95% CI, 0.925–2.039; P = 0.116 for DFS and HR, 1.357; 95% CI, 0.887–2.078; P = 0.160 for OS, respectively) after adjusting for other confounding variables. High pretreatment serum GGT was associated with more advanced tumor behavior, but could not serve as an independent prognostic indicator in patients with early-stage or locally advanced cervical cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22273